Phreesia, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phreesia, Inc. on July 13, 2023. The filing reports corporate governance actions taken by the Board of Directors on the same date, specifically regarding the election of a new director and the adoption of a new equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensation arrangements rather than financial performance results.
Material Changes and Corporate Actions
- Election of Director: Dr. Lisa Egbuonu-Davis was appointed as a Class II Director, serving until the 2024 annual meeting of stockholders.
- Director Compensation:
- Initial RSU Grant: A pro-rated annual grant valued at $177,418, vesting in full upon the earlier of one year from the grant date or the next annual meeting.
- New Hire Grant: An initial grant valued at $185,000 with a four-year vesting schedule (25% annually).
- Adoption of 2023 Inducement Award Plan: The Board adopted a new plan to grant equity incentives as material inducements for new employees under NYSE Rule 303A.08.
- Share Reserve: 500,000 shares of common stock are reserved for grants under this plan.
- Duration: The plan is effective for ten years.
- Administration: Administered by the Board and/or Compensation Committee without stockholder approval.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The document contains standard disclosures regarding the absence of family relationships between the new director and other officers and confirms the execution of a standard indemnification agreement.
Key Facts for Investor Verification
- Verify the total number of shares reserved for the new 2023 Inducement Award Plan (500,000 shares) and its impact on potential dilution.
- Confirm the vesting schedules and total value of equity grants awarded to Dr. Lisa Egbuonu-Davis ($362,418 combined value).
- Review the attached exhibits (10.1, 10.2, 10.3) for specific terms of the Inducement Award Plan and award agreements.
- Note that the Inducement Plan was adopted without stockholder approval pursuant to NYSE Listing Rule 303A.08.